




Altered connectivity of the right anterior insula drives the pain connectome signature in chronic 
knee osteoarthritis 




fMRI Quality Assurance 
A two-step image quality assurance procedure was followed in this study. Firstly, an in-house script 
was run on raw data following guidelines recommended by Friedman and Glover [1]. This script 
creates several outputs per image including: graphs of frequency spectra and mean time series, 
measures of signal-to-noise and signal-fluctuation-to-noise ratio among others. Importantly for this 
dataset, although this other data was calculated, frequency spectra was the clearest indicator of 
poor data quality at this first stage. Examples of good and bad outputs are included in 
supplementary figure 1. Secondly, after preprocessing via FSL Feat, images were once again checked 
for image artefacts and for large amounts of relative motion (as calculated by the MCFLIRT tool – 




Supplementary Figure 1. Examples of frequency spectra calculated 
using in-house scripts to assess raw fMRI data quality that led to data 
being included or excluded from further analysis.  
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Supplementary Figure 2. Brain maps depicting the default mode, salience and central executive 
networks resulting from group independent component analysis. Images are shown in radiographic 
format (right hemisphere is on the left) and thresholded at Z=>3.0 for visualisation. 
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Supplementary Figure 3. A bar graph displaying the group means (+SEM) of calculated dynamic 
functional connectivity over sliding windows starting from sizes of 20 TR’s (40 seconds) up to 50 TR’s 
(100 seconds). Key: dFC – dynamic functional connectivity, STDev – standard deviation, OA – 
osteoarthritis patients, HC – healthy controls, DMN – default mode network, SN – salience network, 







Supplementary figure 4. Graphical visualisation of mean (+SEM) group values for calculated seed-to-
seed Granger Causality coefficients. Key: OA – osteoarthritis patients, HC – healthy controls, rAI – 






Supplementary table 1.   
Significant clusters resulting from ICA analysis of all 44 subjects 
Anatomical regions Cluster extent X Y Z Z-score 
DMN      
   R. Middle frontal gyrus 6549 42 16 48 10.2 
   R. Superior frontal gyrus  22 34 44 9.17 
   R. Frontal pole  14 52 32 7.58 
   R. Paracingulate gyrus  6 44 26 5.86 
   R. Lateral occipital cortex 2094 48 -62 36 12.7 
   R. Posterior cingulate gyrus 1695 6 -52 24 10.4 
   L. Cerebellum 639 -40 -70 -46 5.72 
   L. Angular gyrus 363 -50 -58 30 6.27 
   R. Middle temporal gyrus 244 64 -32 -16 5.38 
   R. Postcentral gyrus 120 -44 -20 48 4.2 
   L. Superior frontal gyrus 38 54 80 60 3.83 
CEN      
   R. Supramarginal gyrus 3677 60 -30 38 10.2 
   R. Precuneus  12 -58 58 5.88 
   R. Planum temporale  64 -24 10 3.08 
   L. Supramarginal gyrus 2157 -58 -36 32 9.68 
   R. Posterior cingulate gyrus 447 10 -34 42 5.38 
   R. Middle frontal gyrus 385 36 34 34 5.07 
   L. Precuneus 236 -10 -60 58 4.82 
   R. Inferior temporal gyrus 107 54 -54 -8 4.38 
SN      
   R. Anterior cingulate gyrus 3211 4 38 12 9.78 
   R. Heschl’s gyrus 468 48 -10 4 5.98 
   L. Heschl’s gyrus 216 -42 -18 8 5.52 
   Brainstem 5 0 -38 -26 3.27 
Images were thresholded at Z>3.0 and reported in MNI152 standard space. Key: 
DMN – Default mode network, SN – Salience network, CEN – Central executive 




Supplementary table 2. 
Demographics of osteoarthritis patients 
Participant Age Sex  Pain 
Duration 
VAS BDI S-Anx T-Anx PCS Mc-S Mc-A Mc-E 
1 54 f 38 26 5 15 25 5 6 0 1 
2 59 f 25 55 9 NA NA NA NA NA NA 
3 59 f 3 35 1 16 25 24 10 2 2 
4 71 f 14 50 1 10 11 1 12 0 1 
5 70 f 10 30 19 22 28 17 22 2 2 
6 81 f 30 60 11 13 16 16 11 0 0 
7 72 m 12 0 4 10 12 1 0 0 0 
8 63 f 20 0 13 18 31 24 12 0 2 
9 56 m 10 20 5 13 13 2 10 0 1 
10 67 m 10 0 7 15 15 7 10 0 0 
11 80 m 10 10 8 10 22 8 11 1 1 
12 84 m 2 60 17 15 35 12 14 0 2 
13 57 m 10 10 8 21 17 1 7 0 2 
14 63 m 9 0 0 17 11 10 0 0 0 
15 61 m 1 10 2 10 15 7 6 0 1 
16 63 m 5 10 1 10 14 2 4 0 1 
17 65 f 6 30 10 15 19 14 1 0 5 
18 65 m 3 32 4 10 18 6 16 2 4 
19 65 f 7.5 40 13 14 18 15 19 4 1 
20 72 f 5 8 14 26 25 34 15 1 3 
21 71 m 4 8 6 10 11 15 11 4 2 
22 72 f 2 70 0 11 23 15 NA NA NA 
23 77 m 20 70 10 12 21 38 16 0 2 
24 56 f 1 0.0 0 11 13 16 15 0 1 
25 65 f 2.5 60.0 19 20 26 28 0 2 0 
Legend: Sex is keyed in as m=male and f=female, VAS – visual analogue score (0-100), BDI – Beck’s 
depression index, S-Anx – State Anxiety, T-Anx – Trait anxiety, PCS – Pain catastrophizing scale, Mc-S 
–  McGill pain questionnaire sensory subscore, Mc-A –  McGill pain questionnaire affective subscore, 
Mc-E – McGill pain questionnaire evaluative subscore, NA – score not available. 
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Supplementary table 3. 
Medicines of osteoarthritis patients 
Participant Medication 
1 tranexamic acid 
2 None taken 
3 None taken 
4 Paracetamol (2 x 500 mg) 3 hours prior to visit 
5 Losartan (25 mg), bendroflumethiazide (2.5 mg), prochlorperazine 
6 None taken 
7 atropine eye drops, maxidex and cosopt eye drops, hypermellose eye drops, 
latanoprost drops 
8 Paracetamol (1000 mg) 8 hours prior to visit 
9 None taken 
10 Glucosamine (100mg), bendroflumethiazide (2.5mg), simvastatin (20mg), contiflow 
(400 microg) 
11 Amlodipine (5mg) 
12 Aspirin (75mg-4 hours prior to visit), paracetamol (x8 last 24h, last taken 4 hours prior 
to visit), simvastatin (40mg) 
13 None taken 
14 Paracetamol (1000mg – taken 2.5 hours prior to visit), aspirin (75mg – taken 4.5 hours 
prior to visit), co-codamol (2 x 500/30mg – taken 15 hours prior to visit), lansoprazole 
(20mg), glucosamine (1000mg) 
15 None taken 
16 None taken 
17 None taken 
18 Bendroflumethiazide (2.5 mg), amlodipine (5 mg), ventolin, tiopsol eye drops, predsol 
eye drops, antibiotic eye drop 
19 Paracetamol (2x500mg – taken 4 hours prior to visit), lansoprazole (30mg), losartan 
20 Ramipril (10mg), Atorvastatin (10mg) 
21 Felodipine (10mg), Ramipril (10mg), Atenolol (100mg), Furosemide (40mg), Warfarin 
(1.5mg), Candesartan (16mg), Gliclazide (80mg), Doxazosin (4mg), Spironolactone 
(4mg), Simvastatin 
22 Oxybutynin (10mg) 
23 Paracetamol (1000mg – taken 1 hour prior to study visit), co-codamol (2x30/500mg- 








Supplementary Table 4 
Demographics of healthy participants 
Participant Age Sex BDI S-Anx T-Anx PCS 
1 59 F 0 10 16 7 
2 70 F 1 14 23 16 
3 59 F 4 10 11 11 
4 65 M 1 19 16 18 
5 68 M 1 10 21 9 
6 57 M NA 10 11 0 
7 51 F 0 10 16 22 
8 66 F 1 11 12 5 
9 58 F 1 NA 17 7 
10 59 M 4 23 14 15 
11 57 F 0 12 17 7 
12 55 F 0 15 20 13 
13 60 F 0 11 18 29 
14 69 F 3 10 20 18 
15 72 M 1 10 16 17 
16 67 M 11 17 23 12 
17 69 M NA NA NA 24 
18 70 M 3 13 13 8 
19 80 F 12 16 21 23 
Legend: Sex is keyed in as m=male and f=female, BDI – Beck’s 
depression index, S-Anx – State Anxiety, T-Anx – Trait anxiety, PCS 










24 None taken 





Supplementary Table 5 
Medications of healthy participants 
Participant Medications 
1 None taken 
2 None taken 
3 None taken 
4 Eye drops for Glaucoma 
5 None taken 
6 None taken 
7 None taken 
8 None taken 
9 None taken 
10 None taken 
11 None taken 
12 None taken 
13# Paracetamol (500 mg - 14.5 hours before visit), 
losartan (100mg, 4.5 hour prior to visit), 
bendroflumethiazide (2.5mg,  4.5 hours prior to 
visit), omeprazole (20mg, 4.5 hours prior to visit)
  
14 Fexfenadine (antihistamine, 3 hours prior to visit) 
15 None taken 
16 Simvastatin (40 mg, 18 hours prior to visit), 
valsartan (40 mg, 18 hours prior to visit), 
lacidipine (4 mg, 18 hours prior to visit) 
17 ramipril  (5 mg), bendroflumethiazide (5 mg), 
amlodipine (5mg) 
18 Simavastatin (25mg, 15 hours prior to visit) 
19 None taken 
Legend: Sex is keyed in as m=male and f=female, BDI – Beck’s depression 
index, S-Anx – State Anxiety, T-Anx – Trait anxiety, PCS – Pain 
catastrophizing scale, NA – score not available. #This subject reported 
having had a fall 9 weeks prior to scanning and suffered from a sore 
shoulder. The paracetamol had been taken prior to sleeping the night 
before the afternoon scan and so likely had been taken to aid sleeping 
and had little to no efficacy by time of scanning.  
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